ArticleThe AAPS journal2025
Long-term Storage Stability of Inhalable Phage Powder Formulations: A Four-Year Study.
Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Wood Hemicellulose-Based Spray-Dried Microencapsulation of a Lytic Bacteriophage Preserves Phage Viability and Improves Control of the Bacterial Wilt Pathogen Ralstonia solanacearum.Microbial biotechnology · 2026Article
- Nano-Enabled Delivery of Phage-Based Antibacterials Against ESKAPE Pathogens.Pharmaceutics · 2026Review
- Inhaled Antibiotic and Biologic Formulations TargetingPharmaceutics · 2026Review
- Bacteriophages targetingFrontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing potential of bacteriophage therapy as an alternative treatment for pulmonary infections caused by multidrug-resistant bacteria has been increasingly recognized. This study aimed to evaluate the long-term stability of spray-dried phage powder formulations for pulmonary delivery, focusing on both biological activity and physicochemical properties. Three phages, PEV1, PEV20, and PEV61, were selected for formulation based on their host range against clinical strains of Pseudomonas aeruginosa. Eight spray-dried formulations, developed with varying proportions of lactose as a stabilizer and leucine as a moisture protectant and powder dispersion enhancer, were stored under controlled conditions at 4°C/15% relative humidity (RH) and 20°C/15% RH for four years. Over this period, phage titers declined with reduction ranging from 0.97 log
Indexed as
Identifiers
40760229What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.